Bio-Techne Corporation (TECH)

518.77 +7.94 (+1.55%) At close: 4:00PM EDT

Bio-Techne Corporation

614 McKinley Place N.E.
Minneapolis, MN 55413
United States
612 379 8854
http://www.bio-techne.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2,600

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Charles R. Kummeth	CEO, Pres & Director	4.69M	26.94M	1960
Mr. James T. Hippel	Exec. VP of Fin. & CFO	1.71M	17.22M	1971
Ms. Brenda S. Furlow J.D.	Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer	1.27M	6.89M	1958
Mr. Norman David Eansor	Pres of Protein Sciences Segment	1.6M	9.03M	1961
Mr. Kim Kelderman	Pres of Diagnostics & Genomics	1.45M	N/A	1967
David Clair	Sr. Director of Investor Relations & Corp. Devel.	N/A	N/A	N/A
Mr. Gerry Andros	VP of Sales and Marketing	N/A	N/A	N/A
Mr. Robert M. Gavin	VP of Corp. Devel.	N/A	N/A	1968
Mr. Struan Robertson	VP of HR	N/A	N/A	N/A
Mr. Kevin S. Gould	Sr. VP of Diagnostics Reagents Division	N/A	N/A	1966

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate governance

Bio-Techne Corporation’s ISS governance QualityScore as of 26 September 2021 is 1. The pillar scores are Audit: 5; Board: 2; Shareholder rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.